The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug data with comprehensive drug target information.
The latest release of DrugBank (version 5.1.5, released 2020-01-03) contains 13,533 drug entries including 2,629 approved small molecule drugs, 1,372 approved biologics (proteins, peptides, vaccines, and allergenics), 131 nutraceuticals and over 6,355 experimental (discovery-phase) drugs. Additionally, 5,211 non-redundant protein (i.e. drug target/enzyme/transporter/carrier) sequences are linked to these drug entries. Each entry contains more than 200 data fields with half of the information being devoted to drug/chemical data and the other half devoted to drug target or protein data.
- MorphineAn opioid agonist used for the relief of moderate to severe acute and chronic pain.
- OxycodoneAn opioid used in the management of moderate to severe pain.
- AcetaminophenAn analgesic drug used alone or in combination with opioids for pain management, and as an antipyretic agent.
- CodeineAn opioid analgesic used to treat moderate to severe pain when the use of an opioid is indicated.
- SalbutamolA beta-2 adrenergic receptor agonist used to treat asthma, bronchitis, COPD, as well as prevent exercise induced bronchospasms.
- Acetylsalicylic acidA salicylate used to treat pain, fever, inflammation, migraines, and reducing the risk of major adverse cardiovascular events.
COVID-19: Finding the Right Fit
Identifying Potential Treatments Using a Data-Driven ApproachDownload the White Paper
Remdesivir, or GS-5734, is an adenosine triphosphate analog first described in the literature in 2016 as a potential treatment for Ebola. In 2017, its activity against the coronavirus family of viruses was also demonstrated. Remdesivir is also being researched as a potential treatment to SARS-CoV2, the coronavirus responsible for COVID-19.
A Year in Review: DrugBank's 2019 Highlights
DrugBank accepted into Creative Destruction Lab - West 2019/20 Cohort
Using DrugBank Data in AI Drug Discovery: A Case Study
DrugBank Fall 2019 Feature Release
Cannabinoids in Epilepsy: A New Era of Treatments
From Discovery to Resistance to Progress
Ketamine: the key to treatment resistant depression?
Tideglusib: From Alzheimer's to Caries Lesion Natural Repair
CFTR Modulators Helping CF Patients Catch Their Breath
New Antivirals Provide Hope for Eradication of Hepatitis C – If You Can Afford It
DrugBank is offered to the public as a freely available resource.
Use and re-distribution of the data, in whole or in part, for commercial purposes (including internal use) requires a license. We ask that users who download significant portions of the database cite the DrugBank paper in any resulting publications.